340 likes | 673 Views
Postdilation of the WINGSPAN- Stent instead of predilation is feasible and safe. Andreas Ragoschke-Schumm 1 , Stephanie Schindhelm 1 , Peter Schmidt 1 , Sascha Schiffler 1 , Andreas Hansch 1 , Robert Drescher 1 , Martin Bokemeyer 1 , Albrecht Günther 2 , Jens Weise 2 , Thomas E. Mayer 1.
E N D
Postdilation of the WINGSPAN- Stent instead of predilation is feasible and safe Andreas Ragoschke-Schumm1, Stephanie Schindhelm1, Peter Schmidt1, Sascha Schiffler1, Andreas Hansch1, Robert Drescher1, Martin Bokemeyer1, Albrecht Günther2, Jens Weise2, Thomas E. Mayer1 Friedrich-Schiller-University, Jena, Germany 1Department of Neuroradiology, 2Department of Neurology
Symptomatic intracranial stenoses • Important cause of stroke, especially in blacks, Asians, and Hispanics. • 10% in the white population • 30% in the chinese population • WASID trial: no benefit of warfarin over ASS but more complications ASS conventional therapy of choice Chimowitz et al. NEJM, 2005
Risk of stroke recurrence Chimowitz et al. NEJM, 2005
Risk of stroke recurrence • Subgroup analyses from WASID: 1 year risk • Stenoses 70-99 % 18 % • Stenoses 70-99 % and qualifying event within 30 d before study enrollment 23%! Kasner et al. Circulation, 2006 Kasner et al. Neurology, 2006
Need for more effective Treatment! One Approach:Intracranial PTA and stenting
WINGSPAN-Stent • Self expanding Nitinol-Stent, Over-The-Wire • Indication: symptomatic intracranial stenoses • Diameter: 2.5 mm – 4.5 mm, length 9, 15, 20 mm
WINGSPAN-Stentmode of deployment According to manufacturer and WINGSPAN-Study
Problem • Predilation poses potential risk of unprotected dissection, vessel occlusion or vessel rupture • There are cases where stenting alone could lead to sufficcient treatment of the stenosis Questions • Does primary Stent-deployment help avoid dilation at all? • Does postdilation harm the stent or the patient?
WINGSPAN-Stentmode of deployment According to our modification
Study • Retrospective • All Patients that were treated with wingspan stents were assessed for technical success • All Patients treated for symptomatic intracranial stenoses were assessed for treatment assocciated complications, periprocedural outcome and restenoses. • Indication: interdisciplinary with a neurologist • Postprocedural follow-up (DSA after 6 months, Doppler/Duplex-Sonography and neurological examination every 3 months during the first year.
results • Observation time 02/2008 - 09/2010 • 34 Patients (25 m, 9 f), Wingspan N=40 • 24 patients were treated with subacute symptomatic stenoses (>24 hrs.) • 9 with acute vessel occlusion (all vertebrobasilar) • 1 with acute aneurysmal SAH (dissection during endovascular embolisation)
Subacute intracranial stenoses • Average stenosis rate 75% (55%-99%) • Age: average 60.7 yrs, (ranging from 43 to 80 yrs.) • Postinterventional follow-up (max. 158 d, median 133 d) • No follow-up in 1 patient
technical results • Stent localisation (28/40) 70% anterior – (12/40) 30% posterior circulation • Technical success (40/40) 100% • Predilation (2/40) 5% • Postdilation (21/40) 52.5% • Dissection C2-Segment during postdilation (asymptomatic but treated with a stent) • Stent deformation (2/40) 5%
Subacute intracranial stenoses-Group • 1 major stroke (basilar artery) with extensive new infarcts in the brainstem and posterior circulation. Death • 1 Patient (proximal MCA) with mild transient neurologic impairment and small new DWI-Lesions in postprocedural MRI (2/24) 8.3% • 1 Patient with mild hyperperfusion Syndrome (headaches) 4.2% • Restenoses (3/24) 12.5% • No intracranial bleedings
Discussion • In 42.5% of Stents no dilation was needed • The rate of 8.3% of periprocedural strokes is within the range of complications reported for intracranial stenting • Restenosis-rate of 12.5% is remarcably low but could increase with longer follow-up. • Visible Stent deformation in 5% but did not impair clinical outcome.
Conclusion • Post- instead of Predilation of the Wingspan-Stent in intracranial stenoses helps avoiding PTA and seems to be safe ??? Lower rate of restenoses ???
Thank you for your attention! E-mail: andreas.ragoschke-schumm@med.uni-jena.de